BR112023018472A2 - Composições de psilocibina, métodos de produção e métodos de uso das mesmas - Google Patents

Composições de psilocibina, métodos de produção e métodos de uso das mesmas

Info

Publication number
BR112023018472A2
BR112023018472A2 BR112023018472A BR112023018472A BR112023018472A2 BR 112023018472 A2 BR112023018472 A2 BR 112023018472A2 BR 112023018472 A BR112023018472 A BR 112023018472A BR 112023018472 A BR112023018472 A BR 112023018472A BR 112023018472 A2 BR112023018472 A2 BR 112023018472A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
psylocybin
production
psilocybin
Prior art date
Application number
BR112023018472A
Other languages
English (en)
Inventor
Philip Elder David
Nigel Richardson
Original Assignee
Compass Pathfinder Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compass Pathfinder Ltd filed Critical Compass Pathfinder Ltd
Publication of BR112023018472A2 publication Critical patent/BR112023018472A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

composições de psilocibina, métodos de produção e métodos de uso das mesmas. a presente divulgação fornece composições farmacêuticas que compreendem uma quantidade terapeuticamente eficaz de psilocibina e um ou mais excipientes farmaceuticamente aceitáveis. são divulgados, também, métodos para produzir tais composições e uso dos mesmos no tratamento de transtornos depressivos.
BR112023018472A 2021-03-30 2022-03-30 Composições de psilocibina, métodos de produção e métodos de uso das mesmas BR112023018472A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163168055P 2021-03-30 2021-03-30
PCT/EP2022/058483 WO2022207746A1 (en) 2021-03-30 2022-03-30 Psilocybin compositions, methods of making and methods of using the same

Publications (1)

Publication Number Publication Date
BR112023018472A2 true BR112023018472A2 (pt) 2023-10-10

Family

ID=81448508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018472A BR112023018472A2 (pt) 2021-03-30 2022-03-30 Composições de psilocibina, métodos de produção e métodos de uso das mesmas

Country Status (12)

Country Link
EP (1) EP4312995A1 (pt)
JP (1) JP2024512983A (pt)
KR (1) KR20230175186A (pt)
CN (1) CN117460498A (pt)
AR (2) AR125250A1 (pt)
AU (1) AU2022246987A1 (pt)
BR (1) BR112023018472A2 (pt)
CA (1) CA3210649A1 (pt)
CO (1) CO2023013050A2 (pt)
IL (1) IL305435A (pt)
TW (1) TW202304466A (pt)
WO (1) WO2022207746A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症
WO2023114097A1 (en) 2021-12-13 2023-06-22 Compass Pathfinder Limited Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006227684B2 (en) 2005-03-23 2012-01-12 Bpsi Holdings, Llc. Agglomerated starch compositions
GB2571696B (en) * 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
BR112021014750A2 (pt) * 2019-01-30 2021-09-28 Diamond Therapeutics Inc. Composições e métodos para gerenciar transtornos
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症
US11766445B2 (en) * 2019-07-18 2023-09-26 Concept Matrix Solutions Oral soft gel capsule containing psychedelic compound

Also Published As

Publication number Publication date
AR126005A1 (es) 2023-08-30
TW202304466A (zh) 2023-02-01
CA3210649A1 (en) 2022-10-06
KR20230175186A (ko) 2023-12-29
CN117460498A (zh) 2024-01-26
IL305435A (en) 2023-10-01
CO2023013050A2 (es) 2023-10-19
EP4312995A1 (en) 2024-02-07
AU2022246987A1 (en) 2023-09-07
JP2024512983A (ja) 2024-03-21
AR125250A1 (es) 2023-06-28
WO2022207746A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
BR112023018472A2 (pt) Composições de psilocibina, métodos de produção e métodos de uso das mesmas
MX2019013954A (es) Inhibidores covalentes de kras.
MX2021005924A (es) Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
BR112019024016A2 (pt) amidas de piridona deuteradas e profármacos das mesmas como moduladores de canais de sódio
BR112022017393A2 (pt) Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
JOP20220130A1 (ar) مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2022013647A (es) Imidazopiridazinas como moduladores de il-17.
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
EP4252755A3 (en) Therapeutic compounds
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
BR112023018237A2 (pt) Fenalquilaminas e métodos para fabricação e uso das mesmas
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
BR112018008835A2 (pt) composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla
MX2022012001A (es) Tratamiento preventivo de la migra?a.